Skip to content

NIH Clinical Center U01 Eligibility Guide

Updated 5 official sources

Quick Answer: NIH Clinical Center Collaborative U01 eligibility in 2026 turns on 8 checks: NIH intramural partner, Clinical Center use, translational question, patient-centric design, pre-application letters, $500,000 direct-cost cap, cooperative-agreement fit, and route choice.

Full answer and how we checked it

NIH Clinical Center Collaborative U01 eligibility in 2026 turns on 8 checks: NIH intramural partner, Clinical Center use, translational question, patient-centric design, pre-application letters, $500,000 direct-cost cap, cooperative-agreement fit, and route choice.

Who this is for: This guide is for extramural PIs, clinical researchers, NIH intramural collaborators, research offices, and translational teams checking whether the NIH Clinical Center U01 is the right route before preparing pre-application materials.

Data note: This guide uses the NIH Clinical Center U01 program page (opens in a new tab), PAR-26-116 full announcement attachment (opens in a new tab), NIH pre-application and letter instructions (opens in a new tab), NIH U01 budget instructions (opens in a new tab), Grants.gov listing 359659 (opens in a new tab), rechecked against the PAR-26-116 announcement on October 9, 2026.

In this guide

Quick Facts

Agency
HHS
Deadline
Mar 6, 2027
Status
Open

Assistance Listing 93.313: all awards

Source: USASpending.gov FY2024

These figures cover all National Institutes of Health awards under Assistance Listing 93.313, of every award type. They are not figures for the award this guide describes, and one award of that kind can be far smaller.

Total Awards (FY2024, whole listing)
6
Avg Award (whole listing)
$2,220,685
Median Award (whole listing)
$2,735,186

Data last verified: May 19, 2026

According to the NIH Clinical Center U01 program page (opens in a new tab), this program is intended for collaboration between extramural investigators and NIH Intramural Research Program investigators using NIH Clinical Center resources and patient populations. According to PAR-26-116 (opens in a new tab), projects that only use banked specimens or data won't be considered for funding.

The real question is whether the project truly needs the NIH Clinical Center. It isn't enough to have an NIH collaborator. The work has to use the Clinical Center in a way that changes the research plan.

Use this guide with the live NIH Clinical Center Collaborative U01 program record, NIH grants complete guide, what is a NOFO, NINDS U01 clinical trial renewal guide, NHLBI early phase R61/R33 guide, Latin America health disparities R01 guide, and the Grantsights grant database.

Source Check

Checked October 2026.

The first PAR-26-116 cycle has passed: new applications were due February 5, 2026, and renewal, resubmission, or revision applications were due March 5, 2026. According to PAR-26-116 (opens in a new tab), the second and last listed cycle is February 5, 2027 for new applications and March 5, 2027 for renewal, resubmission, or revision applications, with review in July 2027, council in October 2027, and an earliest start in December 2027. Applications are due by 5 p.m. local time, and the NOFO expires March 6, 2027. The practical action now is to prepare the LOS request, Clinical Center use case, intramural co-PD/PI role, and full cost map for February 2027.

NIH also says applications must include letters from the Clinical Center and a participating NIH Institute or Center, and the LOS request should be made through the OCRECO process. The Clinical Center letter can address whether study-drug costs are absorbed or must be paid by the grant, the Institute or Center, or an industry sponsor. Grantsights checked the PAR-26-116 key dates table against Grants.gov listing 359659 on October 9, 2026, and the $500,000 ceiling matches. The NOFO also says both letters must be current, meaning dated within 3 months of the application due date, so letters gathered for the 2026 cycle won't carry over. Treat that as a budget and timing gate, not an afterthought.

8 NIH Clinical Center U01 Eligibility Checks

Within 21 days, run 8 stop checks. If the project only needs a collaborator letter, pause.

Stop checkStrong U01 signalRed flag
Intramural partnerNIH intramural investigator has a defined research rolePartner is only advisory
Clinical Center useSome clinical research occurs at the NIH Clinical CenterOnly banked data or specimens are used
Translational questionBasic discovery moves toward clinical applicationProject is ordinary R01 science
Patient-centric designStudy participants, resources, or special population access matterClinical Center use is symbolic
Pre-applicationLOS request plan is realisticLOS process is ignored
BudgetTotal direct costs across recipient, Clinical Center, and intramural costs stay within $500,000 per yearBudget omits Clinical Center or intramural costs
Cooperative agreementTeam accepts substantial NIH involvementTeam expects standard R01 autonomy
Route choiceU01 is compared with R01, R61/R33, R34, and institute-specific clinical-trial routesU01 chosen because it sounds prestigious

According to PAR-26-116, the maximum amount available per application is $500,000 in direct costs per year. NIH says that total includes extramural recipient costs, Clinical Center costs, and intramural investigator costs attributed to the project.

5 Source Facts Applicants Should Know

According to PAR-26-116 (opens in a new tab), project budgets are limited to $500,000 per year in direct costs for up to 4 years, with a possible fifth planning year at a smaller year-1 budget.

The route requires an NIH intramural partner and Clinical Center use, not just a strong research idea.

FactSource-backed read
NOFOPAR-26-116
ActivityU01 cooperative agreement
Clinical trialOptional
Budget$500,000 direct-cost maximum per year across recipient, Clinical Center, and intramural costs
Clinical Center ruleSome clinical research must occur at the NIH Clinical Center
Current timing2026 dates have passed; next dates are February 5, 2027 (new) and March 5, 2027 (renewal, resubmission, revision); expires March 6, 2027

The pre-application process matters. NIH says applicants need letters that confirm Clinical Center resources and institute mission fit.

What NIH Doesn't Tell You

Within 21 days, answer 4 practical questions. First, the Clinical Center has to be central enough to justify the route. A project that could run entirely at the home institution probably belongs elsewhere.

Second, the NIH intramural partner is not a decoration. The application needs a role, effort, responsibilities, and shared work plan.

Third, the budget cap is easy to misunderstand. The $500,000 direct-cost limit includes the recipient, Clinical Center costs, and intramural investigator costs attributed to the project. Don't build a recipient-only budget and discover later that the full project exceeds the cap.

Fourth, drug costs can become a gate. NIH pre-application instructions say the Clinical Center letter can indicate whether study-drug costs are absorbed or paid by the grant, institute, or industry partner.

Grantsights adds that missing layer with award-family context, bad-fit signals, and a 28-day pre-application workflow.

According to NIH, one letter of support comes from the Clinical Center and one comes from the NIH institute expected to accept the U01 application. According to NIH budget instructions, the budget must distinguish recipient costs, intramural investigator costs, and Clinical Center costs. If the project can run entirely outside the Clinical Center, skip this route and choose a better route before building the pre-application.

6 Evidence Assets That Make This Proposal Stronger

Within 28 days, build 6 evidence assets. Asset 1 is the Clinical Center need memo. State which resources, patient populations, procedures, or special capabilities are needed and why they cannot be easily replaced.

Asset 2 is the intramural-collaboration plan. Define who does what, where, when, and how decisions are made.

Asset 3 is the LOS packet. NIH says the pre-application process is needed to obtain Clinical Center and Institute letters of support.

Asset 4 is the cost map. Separate recipient direct costs, Clinical Center costs, intramural investigator costs, drug costs, and any third-party support.

Asset 5 is the clinical-research location table. If some participants are seen outside NIH, show which study activities still occur at the Clinical Center.

Asset 6 is the route memo, the route evidence that shows why this U01 beats the alternatives. Compare this U01 with R01, R34, NHLBI R61/R33, institute clinical-trial routes, and internal NIH collaboration routes.

5 Route Choices Before Drafting

Within 21 days, compare 5 routes.

RouteBetter first read when...Why
PAR-26-116 U01Clinical Center resources and NIH intramural collaboration are core to the studyU01 fits
R01Standard investigator-initiated research can be done outside the Clinical CenterSimpler route may fit
R34Planning or pilot work is needed before a full trialSmaller planning route may fit
R61/R33Product development plus early trial milestones are centralPhased route may fit
Institute-specific trial routeA single IC clinical-trial route fits betterReview home may be clearer

Warning: don't use this U01 for prestige. Use it because NIH Clinical Center resources are necessary.

6 Bad-Fit Signals

First, no NIH intramural investigator has a real role. Second, the project only uses banked specimens or data. Third, the budget ignores Clinical Center costs.

Fourth, the application is a standard R01 with a Clinical Center label. Fifth, the pre-application LOS path is late. Sixth, a participating institute mission fit is uncertain.

U01-fit problems often show up in the collaboration plan. If the plan cannot explain why each partner is needed, the route is not ready.

28-Day U01 Readiness Plan

Days 1 through 4 should write the Clinical Center need memo and partner-role map. Days 5 through 9 should contact the intramural collaborator and institute contacts, then shape the LOS packet.

Days 10 through 15 should build the cost map, patient-location table, and study-drug cost plan. Days 16 through 21 should draft the translational rationale, research strategy, and management plan. Days 22 through 28 should check PAR-26-116, pre-application materials, registrations, and source freshness.

Don't wait until the full application to discover whether the Clinical Center can support the study. That needs to be known before writing.

5 Readiness Signals Before You Request Letters

Within 21 days, check 5 public signals before you start the LOS request. Signal 1 is Clinical Center fit: the project should need NIH Clinical Center resources, patients, procedures, or capabilities.

Signal 2 is partner fit: the NIH intramural collaborator should have a real research role, not only a support letter.

Signal 3 is cost fit: recipient, Clinical Center, intramural, and drug costs should fit the $500,000 direct-cost cap.

Signal 4 is LOS fit: the team needs the Clinical Center and institute letters before the full application path is credible.

Signal 5 is review-home fit: the team should know which participating NIH Institute or Center would accept the application and why its mission fits the study.

5 Real-World Fit Tests For Clinical Center U01 Teams

Within 21 days, test 5 hypothetical examples against PAR-26-116. A hospital with a pediatric rare-disease team, an NIH intramural collaborator, and a need for Clinical Center inpatient procedures has a credible U01 story. According to NIH, at least some clinical research must be conducted at the NIH Clinical Center, so the location of study activity is not a side detail.

A research team with a 1-page concept, patient-flow sketch, NIH intramural partner, and Clinical Center resource request can decide quickly whether the U01 is worth the letter process.

A cancer diagnostics team with an NIH collaborator but no patient visits, special Clinical Center resource, or intramural research role probably has a weak route. The project might still be a good NIH application, but it may belong in an R01, R21, R33, or institute-specific route.

A neurology team planning a first-in-human biomarker study can fit if the Clinical Center provides a patient population, protocol resources, and a genuine intramural co-PD/PI or collaborator role. It gets weaker if the NIH scientist only signs a letter after the science is done.

A company partner can appear in the plan when third-party support or drug costs are relevant, but the U01 budget still has to account for recipient costs, Clinical Center costs, and intramural investigator costs. According to NIH, the $500,000 direct-cost cap covers all three cost types.

A team using only banked samples should stop. PAR-26-116 says applications that only use banked samples or data will be considered non-responsive.

5 Final U01 Review Questions

Before you request letters for the February 2027 cycle, ask 5 review questions. First, can you name the Clinical Center resource and the intramural partner's role in one sentence each? Second, will some study participants be seen at the Clinical Center, not only banked samples or data? Third, does the full cost map stay within $500,000 in direct costs per year?

Fourth, can both letters be dated within 3 months of the due date? Fifth, has the team compared this U01 with R01, R34, R61/R33, and institute-specific routes? If any answer is no, fix it before drafting.

Use this as the final U01 checklist: Clinical Center need, intramural co-PD/PI role, patient-flow location, LOS path, full-cost map, study-drug cost plan, banked-only exclusion, and route comparison. A team that cannot pass that checklist should not treat PAR-26-116 as ready.

Sources

Largest awards active in FY2024

One row per recipient, its largest award | 6 Assistance Listing records | Avg: $2.2M

REAL DATA
1

Augusta University Research Institute, Inc

GA

$3.0M
2

University of North Carolina at Chapel Hill

NC

$2.7M

Use the visible recipient rows as free source context

This program has no reviewed paid report today.

No reviewed paid report is currently offered for this program. The visible source rows remain free.

Next steps

Where to go next

These next pages help you move from research into a specific grant choice.

Frequently Asked Questions

What does PAR-26-116 support?

It supports collaborative translational research between extramural investigators and NIH intramural investigators using the NIH Clinical Center.

Is a clinical trial required?

No. PAR-26-116 is clinical trial optional.

What is the U01 budget cap?

The maximum amount available is $500,000 in direct costs per year, including recipient, Clinical Center, and intramural investigator costs.

What collaboration is required?

Applications must include an NIH intramural scientist as co-PD/PI or collaborator, and some clinical research must occur at the NIH Clinical Center.

Who should skip this route?

Skip it when the project only uses banked specimens or data, lacks an NIH intramural partner, or does not need Clinical Center resources.

Last updated October 9, 2026. Corrected October 9, 2026: what changed. Published by Grantsights from public sources. See our editorial policy, how we build and check guides, corrections and how we make money.